肝胆相照论坛
标题: Replicor发布了12月新临床数据(REP 9AC/REP9AC') [打印本页]
作者: cshbv 时间: 2011-12-14 17:29 标题: Replicor发布了12月新临床数据(REP 9AC/REP9AC')
本帖最后由 cshbv 于 2011-12-14 17:33 编辑
http://www.informedhorizons.com/hepdart2011/pdf/FinalProgram&Abstract%20Book_HEPDART2011.pdf
Abstract 59
Nucleic acid polymers (REP 9AC / REP 9AC’) elicit sustained immunological control of chronic HBV infection
M Al-Mahtab1, M Bazinet2, and A Vaillant2
1 Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh; 2 REPLICor Inc., Montreal, Canada
BACKGROUND: Secreted HBsAg plays a critical role in suppressing host immunity which permits chronic maintenance of HBV infection. REP 9AC / REP 9AC’ are nucleic acid-based amphipathic polymers (NAPs) which inhibit the release of subviral particles from infected hepatocytes. Previous interim clinical data has shown that REP 9AC rapidly clears serum HBsAg in infected patients and allows patients to regain immunological control over their HBV infection. The current clinical experience with REP 9AC and a 4th generation NAP (REP 9AC’) will be presented.
METHODS: All patients were, HBsAg+ with pre-treatment HBV DNA titers between 10^6 and 10^12 copies/ml. REP 9AC or REP 9AC’ was administered by IV infusion. Safety and virologic response (HBV DNA [Roche Cobas], HBsAg anti-HBs (Abbott Architect)] were assessed weekly during treatment.
RESULTS:
(REP 9AC) Treatment achieved > 99.5% reduction of serum HBsAg in seven out of eight patients. Effective clearance of HBsAg and development of anti-HBs were observed as early as 7 days and no later than 32 weeks. All patients responding to REP 9AC achieved a 3 - 7 log reduction in HBV DNA titers and four of these seven patients achieved complete control of their infection with 20-44 weeks of treatment (HBV DNA < 500cpm). Off treatment, three of these four patients are currently experiencing a sustained immunological
control of their infection (HBV DNA < 500cpm, and HBsAg < 10 IU) for 24, 12 and 12 months respectively. The other four patients are experiencing partial immunological control of their infection with sustained > 90% reductions in serum HBsAg and 3-7 log reductions in HBV DNA. Mild pro-inflammatory side effects were consistently observed during drug
administration.(REP 9AC' ). REP 9AC was modified to reduce pro-inflammatory activity and improve compound stability. Early interim data from seven new HBV patients treated with REP 9AC’ show effective clearance or substantial HBsAg reductions in all patients in the first 10 weeks of treatment. Three of these patients have already experienced a 3-4 log decline in their HBV DNA. No pro-inflammatory side effects have been observed to date with REP 9AC’ administration.
CONCLUSIONS: These results demonstrate rapid effective clearance of serum HBsAg by NAPs which appears to allow the restoration of host immunity. In many cases patients experience a durable immunological control after treatment is stopped. These results suggest that NAPs may become an important new tool in the treatment of chronic hepatitis B.
作者: cshbv 时间: 2011-12-14 17:30
核酸聚合物 (REP 9AC / REP 9AC') 引起持续的慢性乙型肝炎病毒感染的免疫调控
M Al Mahtab1、 M Bazinet2 和 Vaillant2
1 班谢赫 Mujib 军医大学，达卡，孟加拉国 ；2 REPLICor Inc.，蒙特利尔，加拿大
背景： 分泌乙型肝炎表面抗原发挥了重要的作用，在抑制宿主免疫，准许慢性乙型肝炎病毒感染的维护。销售代表 9AC / REP 9AC' 是基于核酸的两亲性聚合物 (NAPs) 抑制 subviral 粒子从受感染的肝细胞释放。以前的中期临床数据显示代表 9AC 迅速清除受感染患者血清乙肝表面抗原，并允许病人重新获得他们的乙型肝炎病毒感染的免疫控制权。销售代表 9AC 和第四代 NAP 的当前临床经验 (REP 9AC') 将提交。
方法： 所有的病人，乙型肝炎表面抗原 + 与预处理乙型肝炎病毒 DNA 含量的 10 ^6 和 10 ^12 个拷贝 / 毫升。 代表 9AC 或代表 9AC' 由输液。安全和病毒学响应 (乙型肝炎病毒 DNA [罗什科瓦斯]，乙型肝炎表面抗原抗-HBs (雅培建筑师）] 每周在治疗过程中进行了评估。
结果：
(REP) 9AC治疗取得七出八患者血清乙肝表面抗原的减少 > 99.5%。早在 7 天至迟在 32 周作为观察到的有效间隙的乙型肝炎表面抗原和抗-HBs 的发展。应对代表 9AC 的所有患者都取得乙型肝炎病毒 DNA 滴 3-7 日志减少，这些七名病人的四个方面都取得完全控制其感染治疗 20 44 周 (乙型肝炎病毒 DNA < 500 cpm）。关闭处理，这四名病人的三个目前正在持续免疫
他们的感染控制 (乙型肝炎病毒 DNA < 500 cpm 和乙型肝炎表面抗原 < 10 IU) 24、 12 日和 12 月分别。其他四名病人正在经历部分免疫血清乙肝表面抗原持续 > 90%减少与乙型肝炎病毒 DNA 的 3-7 日志减少他们感染控制。轻度炎症副作用始终如一地观察到在药物
政府当局。(REP 9AC')。销售代表 9AC 做了修改，减少炎症的活动和提高复合的稳定性。早期的临时数据，从七新乙型肝炎患者治疗 REP 9AC' 显示有效间隙或乙肝病毒表面抗原大幅度减少所有患者在治疗前 10 周。在这些患者中的三个已经经历了乙型肝炎病毒 DNA 下降 3-4 日志。没有炎症的副作用已经观察到，迄今代表 9AC' 管理。
结论： 这些研究结果显示快速有效间隙的血清乙肝表面抗原国家行动方案，会出现，允许宿主免疫功能的恢复。在许多情况下病人停止治疗后，遇到持久免疫控制。这些结果表明国家行动方案可能会成为一个重要的新工具，治疗慢性乙型肝炎。
作者: zongguo 时间: 2011-12-14 21:52
怎么还是这8个人啊？为什么没扩大研究啊
作者: lzwp 时间: 2011-12-14 22:40
希望希望！！！！
作者: David_2009 时间: 2011-12-14 23:35
本帖最后由 David_2009 于 2011-12-14 23:40 编辑
我来帮大家解读一下Replicor１２月份的这个会议摘要内容:
首先，原来用REP９AC来治疗８位病人，其中有７位的表抗原HBsag都大幅下降，至少下降了９９。５％（200倍）。这里没有提多少人表抗体Hbsab增加，结合上次一篇摘要来看，似乎所有８人的表抗水平都提高了。参考http://www.hbvhbv.com/forum/thread-1091602-2-2.html
'anti-HBsAg antibodies have been observed in all patients'
7人中，都不同程度的清除了病毒DNA的滴度（病毒胞内复制水平的指标）３－７log。其中４人病毒DNA转阴。停药后，有３人完成血清学转换（１－２年不反弹），也就是说治愈。另外一个人估计是又反弹了还是什么，此处语焉不详细。也许需要更长时间用药才能完全治愈。另外４人Hbsag也都下降了９０％，病毒DNA有３－７log的下降。（似乎有１病人无效）.
但是REP９AC有促进炎症反应的副作用，因此公司对药物进行了改进，开发了降低促炎作用,增加药物稳定性的REP 9AC’。他们又选了７位新的病人做临床实验。结果１０周不到，所有７人的表抗原都下降或完全清除。其中３人病毒DNA下降了３－４个log，没有炎症副反应。（看起来REP 9AC’比REP 9AC效果更好！）
这个结果应该是很振奋的，１５病人中１４个人表抗原Hbsag下降或清除。尤其改进型１００％。有２个问题仍然值得关注:
１表抗下降的人中，有部分人病毒DNA始终不转阴。或停药反弹。（以后结合抗病毒药物联合治疗?）
２ 病人样本仍然很小，希望扩大病历，另外到孟加拉国以外的大国做，这样对我们来说更有信服力。
作者: 咬牙硬挺 时间: 2011-12-15 07:02
不错的消息，是否加用核苷类要效果更好呢
作者: ainile 时间: 2011-12-15 09:23
大家估计什么时间能够上市我们能用上
作者: woaigaoguo 时间: 2011-12-15 09:31
真是个好消息，战友们，坚持，希望就在眼前......
作者: 隽子 时间: 2011-12-15 09:42
本帖最后由 隽子 于 2011-12-15 09:42 编辑
作者: engp7773 时间: 2011-12-15 11:24
是不是该庆祝一下了，这是有史以来最好的
最值得期望的消息了！
作者: StephenW 时间: 2011-12-15 14:10
本帖最后由 StephenW 于 2011-12-15 14:11 编辑
咬牙硬挺 发表于 2011-12-15 07:02 
不错的消息，是否加用核苷类要效果更好呢
是 (根据理论和我们的朋友，studyforhope).
作者: 候月 时间: 2011-12-15 17:34
有什么办法，联系他们到中国来作进一步的研发吗？要加快进度才是！！
作者: zongguo 时间: 2011-12-15 21:38
效果出奇的好，什么时候来中国或者亚洲其他国家做啊
作者: cshbv 时间: 2011-12-15 21:48
本帖最后由 cshbv 于 2011-12-15 21:55 编辑
有人有宽裕资金的话可以考虑投资Replicor，他们现在接受私人投资，并且不打算上市。有更多资金他们应该可以加快临床速度。
非广告，强烈反对没有宽裕资金的人考虑这种高风险的活动。
作者: 咬牙硬挺 时间: 2011-12-15 22:27
凭空臆想一下，论坛里的战友共同出资建立基金为replicor投资，然后三年之后根治乙肝的药物rep 9AC""上市，大家携手脱离苦海转身成为富翁…^_^)Y
作者: 替比佩乐能 时间: 2011-12-15 23:00
作者: javeping 时间: 2011-12-16 10:58
我们发EMAIL过去啊
作者: zongguo 时间: 2011-12-16 21:01
咬牙硬挺 发表于 2011-12-15 22:27
凭空臆想一下，论坛里的战友共同出资建立基金为replicor投资，然后三年之后根治乙肝的药物rep 9AC""上市， ...
这个建议不错，问题是怎么实行
作者: 苹苹苹 时间: 2011-12-17 11:24
懂外语的战友和他们联系下，希望药物能早日用于临床
作者: cshbv 时间: 2011-12-17 20:53
本帖最后由 cshbv 于 2011-12-17 21:01 编辑
苹苹苹 发表于 2011-12-17 11:24
懂外语的战友和他们联系下，希望药物能早日用于临床
很遗憾，这个不是外语的问题，也不是联系的问题，而是临床试验的资金问题。
作者: dongshuning 时间: 2011-12-18 01:55
他们要多少钱？ 有谁能翻译一下他们的资料吗？ 我能弄到钱，多少钱都能弄到！！！
作者: 咬牙硬挺 时间: 2011-12-18 12:41
回复 dongshuning 的帖子
好厉害
作者: 咬牙硬挺 时间: 2011-12-18 12:45
Www.replicor.com是他们公司的网站，上面有联系方式，翻译我不在行。
作者: cshbv 时间: 2011-12-18 14:15
本帖最后由 cshbv 于 2011-12-18 14:25 编辑
dongshuning 发表于 2011-12-18 01:55
他们要多少钱？ 有谁能翻译一下他们的资料吗？ 我能弄到钱，多少钱都能弄到！！！ ...
1. http://www.replicor.com/debut_anglais2.htm
Investor
REPLICor 是一种私人的加拿大公司设在蒙特利尔。我们的股东大多个人和私营公司，分享我们的愿景，创造一种药物具有革命性治疗慢性乙型肝炎患者的潜力。这种药目前对人类的试验阶段。此外，体外和体内能有效对付广泛的其他重要的病毒性感染已显示此相同的药物。
REPLICor 被评为加拿大顶 10 生命科学公司 2004年/2005 年和 2007年-2008 年由渥太华中心研究与创新。
请参见： http://www.topcanadiancompanies.ca/winners/alumni.pdf
定期 REPLICor 寻求新的投资基金。如果您有兴趣成为股东请与公司联系的其他信息。
米歇尔 · 巴齐内
董事会主席兼首席执行官
[email protected]
电话: (514) 496 9016
2. 以前Stephen联系的Replicor董事长的邮件
http://www.hbvhbv.com/forum/thread-1056868-1-1.html
根据Replicor董事长的回信，Replicor目前没有在中国临床试验的计划。不过如果有资金，可能会增加计划。
3. 根据加拿大公司法，Replicor只能接收单笔5w加元以上的私人投资。
作者: StephenW 时间: 2011-12-18 14:19
本帖最后由 StephenW 于 2011-12-18 14:20 编辑
回复 dongshuning 的帖子
他们接受投资，风险自负。投资的最低金额为50,000加拿大元。
最好的办法是hbvers形成一个集团，以收购该公司。
作者: 布隆方丹 时间: 2011-12-18 15:16
StephenW 发表于 2011-12-18 14:19
回复 dongshuning 的帖子
他们接受投资，风险自负。投资的最低金额为50,000加拿大元。
这个设想很好，有远见，不过估计实施起来很难
作者: zongguo 时间: 2011-12-18 23:19
StephenW 发表于 2011-12-18 14:19
回复 dongshuning 的帖子
他们接受投资，风险自负。投资的最低金额为50,000加拿大元。
论坛搞个基金，或者哪个携带者企业家可以收购那公司
作者: 8770122 时间: 2011-12-19 10:43
回复 StephenW 的帖子
可以呀 您可以先期了解如何操作这类事情？公司声誉如何，基金会如何成立，如何推广等！我支持。
作者: 8770122 时间: 2011-12-19 10:57
回复 dongshuning 的帖子
俺那口子英语专业八级 可以的 就是指不动 呵呵
作者: StephenW 时间: 2011-12-19 13:00
回复 David_2009 的帖子
A comment by our MEdHelp friend, studyforhope, on the efficacy of REP9AC:
The artificial temporary blocking of surface antigen release unleashes a powerful immune response against previously unattacked HbSAg epitopes ( by Tcell exhaustion (class I and II!) by antigen overexposure and other blocking effects) and other portions of the surface antigen.
When this effect is insufficient to reduce the VL to UND - as was the case in 4 out of the seven - we must assume an adaptive response in the viral genome of the critical response elements in the surface antigen protein so as to evade some of the immunological mechanisms now present
or
an inherent incapacity of a particular patient to mount a suffcient strength response regardless of resistance adaptations in the surface antigen response elements.
the first problem could be overcome by antiviral cotreatment to reduce the adaptive/mutational power. Then the HBV system will respond to the desired end -UND and SVR.
The second situation is hopefully rare. Since a substantial reduction in cccDNA during replicor therapy is nevertheless expected to happen in most of such patients, the maintenance of that blissful state will have to come by external help, that is by continuing antivirals or hopefully with a permanent reinfection blocker -likely Myrcludex- that has -again hopefully- less side effects than lifelong antivirals.
Overall the surface antigen blockage should become a powerful new tool , used wisely in optimized combinations to achieve a state of permanently improved health for chronic HBV patients.
我们MEdHelp朋友，studyforhope，一个REP9AC疗效评价：
表面抗原释放的人工暂堵释放出一个强大的免疫反应，对以前unattacked的乙肝表面抗原表位（Tcell用尽抗原曝光过度和其他阻断作用（I类和II））和其他部分的表面抗原。
当这种影响是不够的，以减少对VL(viral load) to UND(undetected) - 的情况一样，在4/7个 - 我们必须假设病毒基因组中的关键反应元件的表面抗原蛋白的适应性反应，以逃避一些现在提出免疫机制
或
固有的特定病人丧失工作能力，不管阻力适应安装足够的强度响应表面抗原反应元素。
第一个问题是可以克服抗病毒药物cotreatment减少自适应/突变
功率
。 HBV的系统，然后将响应所需的结束，UND(undetected)和SVR。
第二种情况是希望罕见。由于在cccDNA的replicor治疗期间的大幅减少但预计在大多数这类病人发生，维护，幸福的状态，或希望与一个永久的再感染受体阻滞剂可能会向外部的帮助下，继续抗病毒药物来Myrcludex已再次希望小于终身抗病毒药物的副作用。
总体而言，表面抗原堵塞应成为一个强大的新工具，用于明智的优化组合，以实现永久改善慢性乙型肝炎患者的健康状态。
作者: David_2009 时间: 2011-12-19 18:59
回复 StephenW 的帖子
I agree. Here is my point:
The cccDNA have the half-life. This cccDNA pool needs to be recharged by the newly synthesized infective HBV or recycling of HBV core element intracelluarly. So by REP 9AC, we could block the infective HBV, however the cccDNA pool could still be recharged by the intrcelluarly replication recycling. Then the nucleoside analogous could inhibit the viral DNA polymerase, thus totally stop the cccDNA's renew. After several passge of cccDNA half-life, they will finally disappear.
作者: StephenW 时间: 2011-12-19 19:15
回复 David_2009 的帖子
REP9AC does not block new infection, it only blocks the release of non-viral HBsAg. This is expected to restore immune attack against infected liver cells, thereby clearing infected liver cells (together with their pools of cccDNA) from the liver.
Since REP9AC does not block the release of new virions from infected liver cells and the recharging of the cccDNA pool, it needs some help. To block re-infection by released new virions, studyforhope suggested using Mycrludex. To block the production of new virions and recharging of the cccDNA pool, studyforhope suggested the use of antvirals.
These are all theoretical conjectures, we hope they will pan out in real life.
作者: David_2009 时间: 2011-12-19 20:33
本帖最后由 David_2009 于 2011-12-20 00:06 编辑
回复 StephenW 的帖子
Mycrludex, as it claimed, could somehow inhibit the re-infection of HB virion into hepatocyte. However, it's still a problem that it unable to block the intracelluar recycling of HB virion. Thus, the cccDNA still has the chance to be recharged by this way ... Besides, the Mycrludex is just in the Phase I...
On the other side, NA I think could supress the viral retro-transtriptase, hence completely block the cccDNA recharging. This will be followed by the gradually decreasing of cccDNA. e.g Tenofovir, 6 years' clinical data shows no drug tolerance and is commercial available now. Could it be a choice?
Anyway, it is just my expectation and hope
作者: 咬牙硬挺 时间: 2011-12-20 02:10
如果成立基金会，会有多少人参与呢？毕竟讨论和行动是有区别的啊
作者: yiganxiaosan 时间: 2011-12-21 10:01
David_2009 发表于 2011-12-19 20:33
回复 StephenW 的帖子
Mycrludex, as it claimed, could somehow inhibit the re-infection of HB virion ...
i don't understand why REP 9RC just carry out in such a small coutry, there are so many patients in China, why they do not carry out in China with the money they have? does it expensive to be in China?
another question, is the people in China is the same as in Africa? if it work for Africans, it will work for all human being, right?
作者: StephenW 时间: 2011-12-21 12:59
I don't know the answer. I am guessing:
1. to conduct a clinical trial in China, you will need the approval of sFDA, this may take time and costly;
2. you will need a local partner. Replicor had research co-operations with Chinese institutions:
Fourth Military Medical University (People’s Republic of China)
Tropical Medicine Institute of Guangzhou, University of Traditional Chinese Medicine, China
Finally, Bangladesh is in south-east Asia (between India and Burma). REP9AC interacts with the HBsAg, so it should work for everyone. Of course, it still needs to go through all clinical trial stages.
作者: yiganxiaosan 时间: 2011-12-21 13:04
StephenW 发表于 2011-12-21 12:59
I don't know the answer. I am guessing:
1. to conduct a clinical trial in China, you will need the a ...
are you in American or somewhere?
作者: StephenW 时间: 2011-12-21 13:11
回复 yiganxiaosan 的帖子
Australia
作者: yiganxiaosan 时间: 2011-12-21 13:12
StephenW 发表于 2011-12-21 13:11
回复 yiganxiaosan 的帖子
Australia
what's your job? are you a HBVer ?
you post a lot of article here
作者: StephenW 时间: 2011-12-21 13:18
回复 yiganxiaosan 的帖子
Retired, ex-computer programmer.
作者: cshbv 时间: 2011-12-21 17:55
本帖最后由 cshbv 于 2011-12-21 17:57 编辑
yiganxiaosan 发表于 2011-12-21 10:01
i don't understand why REP 9RC just carry out in such a small coutry, there are so many patients i ...
其实很容易理解，中国对知识产权的保护缺乏。他们是个小公司，来中国试验，无法保证自己的知识产权不被窃取。申请专利，以及对专利的法律诉讼和与政府的关系，这些都是成本。在中国做试验虽然人力成本低廉，但总成本高昂，所以很容易理解他们为何不在中国做试验。
不过我觉得很难理解的是为什么他们不在西方国家做试验，比如Myrcludex-B是在德国做试验的。
作者: MP4 时间: 2011-12-21 20:27
本帖最后由 MP4 于 2011-12-21 23:39 编辑
孟加拉临床试验便宜,而且米国FDA承认外国试验,并且监管少,伦理委员会什么的。
而且米国本土缺乏HBVer.
Myrcludex-B本来就是德国研制的,而且欧洲还有一定HBVer,母婴传播的少。
http://news.sina.com.cn/w/sd/2010-12-28/154421721239.shtml
作者: a46346310 时间: 2011-12-21 22:03
我打算策划针对全国乙肝病人募集大量资金，成立基金，或者把钱交由专业的基金机构管理，比如像李连杰壹基金之类的。把每年募集的资金专门用来开发治疗乙肝药物，资助基础研究，前言研究等等不同层面的科学研究，设立创新大奖等。只要有钱加上科学的管理。不敢说一定可以治愈乙肝，当起码可以大大推进更好药物的开发。
当然前期资金的募集方法一定要创新，需要一个事件营销。前期必需有充分的准备，一炮打响。不然很难募集到足够的资金，起码需要亿算，而且每年都要有。等过段时间我会好好想想从哪里开始操作，先提供个想法，看看大家觉得怎么样！
作者: cshbv 时间: 2011-12-21 23:25
MP4 发表于 2011-12-21 20:27
孟加拉临床试验便宜,而且米国FDA承认外国试验,并且监管少,伦理委员会什么的。
而且米国本土缺乏HBVer.
Myrc ...
美国本土并不缺乏HBVer，全球最大的乙肝市场就是美国，它有1百万携带者，区区几个临床试验患者肯定是可以找到的。
Myrcludex-B在德国发明，就在德国试验。
而rep9ac的发明和商业化与澳大利亚和加拿大都有关系，为何不在美国，或者这两个地方做呢？
孟加拉临床试验便宜确实是原因之一。但临床试验便宜的国家很多（中国并不便宜），为何是在孟加拉做？
作者: ybdn 时间: 2011-12-22 06:27
cshbv 发表于 2011-12-21 17:55
其实很容易理解，中国对知识产权的保护缺乏。他们是个小公司，来中国试验，无法保证自己的知识产权不被窃 ...
孟加拉国的知识产权保护比中国大陆强？这是没有根据的。
就算中国大陆保护不强，他们也可以在大陆做实验，到欧美去赚钱。
要是大陆不保护他们，他们在欧美做完实验，大陆照样可以不保护他们的产权。
所以，不要妖魔化GCD。
作者: 布隆方丹 时间: 2011-12-22 08:52
如果筹不到钱，他们是否要推迟临床试验？
真是资本家啊
作者: bluehawk 时间: 2011-12-22 09:46
cshbv 发表于 2011-12-21 23:25
美国本土并不缺乏HBVer，全球最大的乙肝市场就是美国，它有1百万携带者，区区几个临床试验患者肯定是可以 ...
找找以前的帖子，记得有帖子说过REP 9AC重要负责人是孟加拉人。
作者: yiganxiaosan 时间: 2011-12-22 09:51
bluehawk 发表于 2011-12-22 09:46
找找以前的帖子，记得有帖子说过REP 9AC重要负责人是孟加拉人。
这个理由还是可信的，不然就很难理解为何要在孟加拉做了。
不管怎么样，能说得通，就说明这个药是真的，而且是有效的。
作者: 咬牙硬挺 时间: 2011-12-22 10:00
回复 a46346310 的帖子
如果成立了我一定支持
作者: StephenW 时间: 2011-12-22 13:52
本帖最后由 StephenW 于 2011-12-22 13:53 编辑
回复 bluehawk 的帖子
"找找以前的帖子，记得有帖子说过REP 9AC重要负责人是孟加拉人。" - 不是.发明者和行政总裁都是加拿大人. 负责临床试验的医生，当然是一个孟加拉人.
作者: 8770122 时间: 2011-12-22 20:50
回复 a46346310 的帖子
可以沟通一下 QQ1306670810
作者: yiganxiaosan 时间: 2011-12-23 10:26
StephenW 发表于 2011-12-19 13:00
回复 David_2009 的帖子
i think you are very professional, even than some doctors, can you search my post "体检归来" ， and can you explain more about my condition? thank you very much!
我从96年上大学才知道小三阳携带，具体感染时间不详。99年发病过一次，转氨酶150多，但是那时查出来了戊肝病毒，因此不知道是不是乙肝发病，这十几年来一直查肝功，都是30以上，30-33之间，比较稳定，但是都这么高。
以下是近期检查结果，请大家来看看，有问题吗？
肝功基本正常，ATL 31，DNA 4.7*10E3 弱阳，B超回声增粗，粗糙，这种情况怎么样？
作者: StephenW 时间: 2011-12-23 12:15
回复 yiganxiaosan 的帖子
I am not a doctor and I have zero clinical experience. So it is just my opinion, don't treat it too seriously.
It is about your husband, right? I think he is doing well, low hbvdna and very normal ALT. So I suggest he should just have half-yearly checkup. I know nothing about ultrasound. I would just look at the comments by the specialist doing the ultrasound - it mentions not concerns, so why worry?
What is the result of his Fibroscan?
作者: yiganxiaosan 时间: 2011-12-23 12:20
StephenW 发表于 2011-12-23 12:15
回复 yiganxiaosan 的帖子
I am not a doctor and I have zero clinical experience. So it is just my op ...
yes, you know me, it's my husband. his fibo has not come out yet.
but some experts said that, DNA positive for Xiao sanyang, is really dangerous, and if ATL >30 for man,it's even worse, i feel so worry since i know the turth and angry for being cheated, i still can not accept all this yet!
作者: StephenW 时间: 2011-12-23 12:51
本帖最后由 StephenW 于 2011-12-23 12:55 编辑
回复 yiganxiaosan 的帖子
A few years ago, they cannot detect hbvdna under a 1000 IU/ml. So the tests are getting more sensitive. "Undetected" does not mean 0 hbvdna. Experts say, some new viruses are always replicating inside the infected liver, they are just too low to be detected in the serum.
His ALT is close to 30, so it indicates no damage to the liver.
Don't watch the numbers all the time. They fluctuate all the times - I was told they can change between morning and evening
P.S. Elevated ALT and hbvdna over a long period of time may cause fibrosis/progression of fibrosis. But it can be treated.
作者: yiganxiaosan 时间: 2011-12-23 13:04
StephenW 发表于 2011-12-23 12:51
回复 yiganxiaosan 的帖子
A few years ago, they cannot detect hbvdna under a 1000 IU/ml. So the test ...
thank you for your omfort, i don't know what can do now? i hope everything will be OK,
Whether my marriage go on or not.
作者: yiganxiaosan 时间: 2011-12-23 13:05
StephenW 发表于 2011-12-23 12:51
回复 yiganxiaosan 的帖子
A few years ago, they cannot detect hbvdna under a 1000 IU/ml. So the test ...
Acturally his ATL is over 30 for more than ten years, he check it for past 15 years, it is very steabile, stay around 30-33, does it tell something?
作者: StephenW 时间: 2011-12-23 13:31
回复 yiganxiaosan 的帖子
In the past, under 40 is considered normal. So, if his ALTs have been around 30, he is doing better than most hbvers.
Generally, HepB is a slow moving disease, it is chronic, but most hbvers die with HepB than from it.
Personally, I think your husband was wrong in not telling you. You have every right to be angry at him. Don't stress yourself too much and take care.
作者: 布隆方丹 时间: 2011-12-24 10:20
全世界饱受hbv折磨的患者翘首以待
作者: yiganxiaosan 时间: 2011-12-26 12:26
StephenW 发表于 2011-12-23 13:31
回复 yiganxiaosan 的帖子
In the past, under 40 is considered normal. So, if his ALTs have been arou ...
the sickness rate of HBVer is 30%, i really think it's very horible
作者: StephenW 时间: 2011-12-26 15:33
回复 yiganxiaosan 的帖子
Yes, it is. But the death rate is 100%
Seriously, this 30% is old data, with the advent of antivirals, healthier living (no smoking, no drinking), early detection of cancer, and better treatments, you will find this number is no longer true. I have no proof, but Old Wong commented he was seeing much less cancer patients in recent years.
A very wise reader once said, once you are born, the next certainty is death.
作者: yiganxiaosan 时间: 2011-12-26 15:47
StephenW 发表于 2011-12-26 15:33
回复 yiganxiaosan 的帖子
Yes, it is. But the death rate is 100%
i don't know, i was worry aobut that all the time since i know the truth, i still do not figure out what i should do.
作者: StephenW 时间: 2011-12-26 16:26
回复 yiganxiaosan 的帖子
You are right to be worried, especially since you discovered the illness recently. This is a natural reaction. In time, by finding out more about HepB, you will worry less. What you must do is to keep half-yearly checkup and as Lyq2003526 often said: get treated when it is necessary (and be prepared to be treated for a long period of time).
But I know you have to convince your other half to see it your way. Here I am intruding into your private space, so I apologize if I am offending you. Some men are ostrichs, they prefer to put their heads in the sand than to see a doctor. In Australia, most older men refuse to screen for prostate and colon cancer until it is too late. The reasons are complex, of course. Personally, I think, if there are more effective treatments, most men will lose their fear and reluctance to seek treatment. In China, there is another factor to HepB, discrimination. This too is fading, but no fast enough. I notice in the last year or so, there is more awareness about HepB, even in the USA, President Obama has signed a bill to tackle HepB. India and Pakistan are now facing up to their HepB problems. With globalization, HepB is now an international problem. China already knows it has an enormous problem with its large population of hbvers, hopefully, it will not only invest in finding a cure but also do something about removing the stigma associated with HepB.
作者: yiganxiaosan 时间: 2011-12-26 17:22
StephenW 发表于 2011-12-26 16:26
回复 yiganxiaosan 的帖子
You are right to be worried, especially since you discovered the illness r ...
it doesn't matter,i don't mind you read my posts. i do not know who should i talk to, i know he would like to keep it a secret, but i was so sorrow and so angry, i still do not what to do, who can help me, i post all my words here, want to get some comfort or get some suggentions, obviously, on body can make the decision for me, but i just want to let off myselfe....
i do not know whether i can accept this yet, maybe not, maybe can after a long time, i am entangled with this for almost 3 months. i am a weak girl, not so strong, i am afraid to face the unknown devil in future...i don't know what to do
作者: StephenW 时间: 2011-12-26 18:01
回复 yiganxiaosan 的帖子
I am out of my depth here. I am guessing: I think you can accept his illness, but you are deeply hurt by his not telling you. This is made worst by him not acknowledging that he was wrong. You also need him to face up to his illness.
In the western culture, this is what they will do:
1. the couple should see a marriage counselor;
2. trial separation.
Chinese culture is still conservative....
As I said before, don't stress yourself - give yourself a few months to see how things work out. Is there a need to make a quick decision? Do take care. As I am fond of say: "sleep on it".
作者: zongguo 时间: 2011-12-26 21:31
楼上发帖为什么不用中文
作者: yiganxiaosan 时间: 2011-12-27 11:09
StephenW 发表于 2011-12-26 18:01
回复 yiganxiaosan 的帖子
I am out of my depth here. I am guessing: I think you can accept his illne ...
i am really appreciate your words.
It's out of my capacity, he think i have mental trouble for being here, and think this thing all the time, strugling all the time, i think we do need some help, but he don't think it's his problem, all mine.
作者: StephenW 时间: 2011-12-27 13:28
回复 yiganxiaosan 的帖子
All these times, I forgot to mention that you should get vaccinated.
There is a saying: stop digging when you are in a hole. If you argue with him, he will dig deeper. So let him be, he will stop digging, and may even jump out of the hole, soon.
作者: 咬牙硬挺 时间: 2011-12-27 22:25
replicor的网站今天上不了了，担心
作者: zongguo 时间: 2011-12-27 23:12
咬牙硬挺 发表于 2011-12-27 22:25
replicor的网站今天上不了了，担心
是在更新吗
作者: 苹苹苹 时间: 2011-12-31 17:52
有新消息吗
作者: cshbv 时间: 2011-12-31 19:06
在http://www.hbvhbv.com/forum/thread-1100447-3-1.html有提到个新数据的发布。
台湾2-3月APASL2012 (http://www.apasl2012taipei.org/f ... STRACTS20111223.pdf). Replicor会公布更新数据。
会议有大量中国研究人员参加，可能可以借这个机会牵线搭桥，让Replicor到大陆来. 不知道卫生部，科技部之类有没有这个想法。
作者: zongguo 时间: 2011-12-31 20:10
cshbv 发表于 2011-12-31 19:06
在http://www.hbvhbv.com/forum/thread-1100447-3-1.html有提到个新数据的发布。
台湾2-3月APASL2012 (htt ...
其实能在台湾做临床试验也不错了
作者: cshbv 时间: 2011-12-31 23:13
本帖最后由 cshbv 于 2011-12-31 23:14 编辑
zongguo 发表于 2011-12-31 20:10
其实能在台湾做临床试验也不错了
台湾的会议却没有台湾的研究者参与，70%都是中国大陆的研究人员，虽然大部分都是无关痛痒的研究。台湾由于80年代就实行了强制疫苗计划，现在台湾感染率已经降低很多，大概也不大关注hbv的创新研究了。希望组织这次会议的人能够把加拿大的技术带到台湾，带到大陆。
作者: MP4 时间: 2012-1-1 01:12
cshbv 发表于 2011-12-31 23:13
台湾的会议却没有台湾的研究者参与，70%都是中国大陆的研究人员，虽然大部分都是无关痛痒的研究。台湾由于 ...
你看清楚吧，越南都有怎会没台湾。一大堆TW的。台湾感染率和大陆差不多啊。
作者: 咬牙硬挺 时间: 2012-1-1 08:39
期待
作者: StephenW 时间: 2012-1-1 15:32
回复 咬牙硬挺 的帖子
APASL 2012 - Some of the invited distinguished speakers:
Stephen A. Locarnini Australia Melbourne
Lai Wei China Beijing
Yu-Mei Wen China Shanghai
Anna S. F. Lok United States Michigan
作者: 咬牙硬挺 时间: 2012-1-2 13:16
回复 StephenW 的帖子
魏来也参加会议啊，吴玉章也参加就好了
作者: zongguo 时间: 2012-1-4 22:53
咬牙硬挺 发表于 2012-1-2 13:16
回复 StephenW 的帖子
魏来也参加会议啊，吴玉章也参加就好了
吴玉章 骗子而已
作者: 咬牙硬挺 时间: 2012-1-5 07:37
合成肽的二期完整揭盲数据明日公布，适当关注一下
作者: zhjf227 时间: 2012-1-5 10:11
令人振奋啊！ 希望扩大试验范围，提供更多后继消息！
作者: javeping 时间: 2012-1-5 15:48
天天上来看，有没有新消息
作者: 昨天的记忆 时间: 2012-1-5 23:39
作者: 贫瘠的土 时间: 2012-1-6 11:03
“这些结果表明国家行动方案可能会成为一个重要的新工具，治疗慢性乙型肝炎。”
这句话说的很保守，感觉文字游戏中，因为每一类药物都可以这么说！
作者: zongguo 时间: 2012-1-9 20:01
最近有消息吗
作者: zongguo 时间: 2012-1-11 22:21
什么时候才能上市啊
作者: yiganxiaosan 时间: 2012-1-12 12:01
cshbv 发表于 2011-12-14 17:30
核酸聚合物 (REP 9AC / REP 9AC') 引起持续的慢性乙型肝炎病毒感染的免疫调控
M Al Mahtab1、 M Bazinet2 ...
其实最主要的是清楚CCDNA，因为这个东西是罪魁祸首，不知道这个药是不是只是清除了S抗原，而ccDNA还是在肝细胞中呢？谁知道？
作者: StephenW 时间: 2012-1-12 16:59
本帖最后由 StephenW 于 2012-1-12 17:00 编辑
回复 yiganxiaosan 的帖子
REP9AC阻止HBsAg颗粒从被感染的肝细胞的释放.
这容许我们的免疫系统清除和控制乙肝.
[attach]272467[/attach]
[attach]272467[/attach]
作者: jsmscym 时间: 2012-1-12 17:03
还不知道是否跟重庆啤酒一样，半途夭折吧。
作者: 候月 时间: 2012-1-12 20:12
其实，这个药应该来中国谋取合作，效果和速度将极大提高。
乙克和重啤一下子就搞了几百人试验，搞到如今劳民伤财，令人如骨埂喉！如果试的是这个药，那情形可能大不相同了。可能大家都有救了。
有没有人尝试过联系？？
作者: zongguo 时间: 2012-1-13 00:20
如果重庆啤酒搞这个药，估计现在成功了，股价升天了
作者: nancyling 时间: 2012-1-13 16:52
都是扯淡玩意！降低药价是根本！
作者: zongguo 时间: 2012-1-14 19:29
nancyling 发表于 2012-1-13 16:52
都是扯淡玩意！降低药价是根本！
国外的东西还是比较靠谱的
作者: levopang 时间: 2012-1-15 16:21
希望带来惊喜吧。
作者: waitingboy 时间: 2012-1-16 09:38
希望
作者: 苹苹苹 时间: 2012-1-19 12:23
早点出来吧，大家都等不及啦
作者: cshbv 时间: 2012-1-21 12:03
本帖最后由 cshbv 于 2012-1-21 12:09 编辑
APASL2012的网站好像打不开了。。。不知道会不会影响Replicor.
作者: 0a0a 时间: 2012-5-28 23:43
快来中国吧，不管那么多，搞个诊所，打个广告，直接上药。我日他奶奶的，中国有多少骗子诊所专治乙肝都发了大财，何况你们是真能治病啊！
作者: cwy121 时间: 2012-6-2 14:38
我估计这玩意儿没戏。要有的话，国内不早就吵得沸沸扬扬了。现在国内都没人提他，都说他在忽悠钱。只注重投资。
作者: azure_china 时间: 2012-6-20 16:38
回复 dongshuning 的帖子
这个确实需要大家的关注和参与 毕竟钱可以再挣 可生命是不可等待的
| 欢迎光临 肝胆相照论坛 (http://hbvhbv.info/forum/) |
Powered by Discuz! X1.5 |